35 results
8-K
EX-10.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
of the first patient in such trial (e.g., pursuant to an agreement with or statement from the FDA or the EMA on a ‘Special Protocol Assessment’ or equivalent
8-K
EX-99.4
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
an assessment of the inputs used in determining the reported fair values. ASC Topic 820, Fair Value Measurement,
establishes a hierarchy of inputs used
8-K
EX-99.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
Patent and Trademark Office (“USPTO”), may not agree with our assessment of whether such patent term extensions or adjustments should be granted
DEFM14A
ELYM
Eliem Therapeutics Inc
4 Jun 24
Proxy related to merger
8:00am
with respect to taxes, settle or compromise any liability, claim or assessment in respect of material taxes or surrender any right to claim a material refund … , settle or compromise any liability, claim or assessment in respect of material taxes, or surrender any right to claim a material refund of taxes;
enter
PREM14A
ELYM
Eliem Therapeutics Inc
17 May 24
Preliminary proxy related to merger
4:36pm
with respect to taxes, settle or compromise any liability, claim or assessment in respect of material taxes or surrender any right to claim a material … to taxes, settle or compromise any liability, claim or assessment in respect of material taxes, or surrender any right to claim a material refund
DEFA14A
pxvocgbvg8ihur2p
11 Apr 24
Additional proxy soliciting materials
8:10am
8-K
EX-2.1
1n0e1
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
53vgjb
20 Dec 22
Departure of Directors or Certain Officers
4:02pm
8-K
EX-99.2
ega2o0zlx2rt
14 Nov 22
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights
6:10am